Submitted to the US Agency for International Development by the
Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program.
This manual provides a framework to identify problems and design interventions to improve access to and use of medicines for children. It is a resource for ...both health policy makers and health system managers and presents a structured approach to the steps introduced in the framework in the context of child health.
more
National Tuberculosis and Leprosy Conrol Programme
La crise humanitaire récente qui a sévit en Centrafrique a entrainé l’arrivée d’un nombre important d’acteurs humanitaires dans le pays, afin de pouvoir répondre aux besoins considérables des populations vulnérables. Cet afflux d’acteurs humanitaires, combiné aux changements politico...-sécuritaires dans le pays, ont eu pour conséquence, entres autres, de rendre plus difficile, et l’importation de biens nécessaires à l’assistance humanitaire dans le pays. En effet, bien que la Lois des finances ( 2015) et différends Arrêtés
more
Depuis la déclaration des premiers cas de sida au Burkina Faso, les programmes nationaux successifs de lutte contre l’épidémie ont totalement occulté les enjeux sanitaires liés à la consommation de produits psychoactifs. Ainsi, ce n’est qu’en 2010 que les usagers-ères de drogues ont ét...é inclus-es dans la liste des groupes vulnérables ciblés par le Cadre National Stratégique 2011-2015. En dehors des publications officielles, qui traitent les drogues sous l’angle de la criminalité, et de l’étude menée par l’association communautaire Kasabati en 2011, limitée à la ville de Ouagadougou, peu de travaux ont été réalisés pour déterminer l’impact de la consommation de produits psychoactifs sur la dynamique de l’épidémie à VIH.
more
The World Health Organization (WHO) has recommended a universal antiretroviral therapy (ART) for all HIVinfected children before the age of two since 2010, but this implies an early identification of these infants. We described the Prevention of Mother-to-Child HIV Transmission (PMTCT) cascade, the ...staffing and the quality of infrastructures in pediatric HIV care facilities, in Ouagadougou, Burkina Faso.
more
Q&A on COVID-19, HIV and antiretrovirals - Hỏi Đáp về COVID-19, HIV và thuốc antiretrovirals (ARVs)
Please find all relevant guidelines and information on antimicrobial resistance AMR in our new AMR TOOLBOX
www.amrbox.org
L’ivermectine est un médicament antiparasitaire approuvé pour le traitement des infections parasitaires, y compris la strongyloïdose et l’onchocercose, chez l’être humain. Récemment, on a indiqué une augmentation de l’utilisation de l’ivermectine pour la prévention et le traitement ...de la COVID-19 par le public dans les États membres de l’Union africaine. Actuellement, il n’y a : 1. Aucune preuve scientifique provenant d’études précliniques sur l’effet thérapeutique de l’ivermectine pour le traitement de COVID-19 2. Aucune preuve de son efficacité clinique pour la prise en charge de patients présentant une COVID-19 asymptomatique, légère, modérée ou sévère 3. Aucune donnée de sécurité concernant l’utilisation de l’ivermectine pour la COVID-19 dans la majorité des études publié
more
at the World Trade Organization (WTO) Trade Related Aspects of Intellectual Property Rights (TRIPs) Council
23 Febur. 2021
The purpose of this document is to provide relevant information and guidelines on
coronavirus outbreaks – and in particular the novel coronavirus SARS-CoV-2 and the
diseases it produces, COVID-19 – for pharmacists and the pharmacy workforce, both in a
primary care context (i.e. community phar...macies and primary healthcare facilities) and in
hospital settings, as well as for pharmacists working as clinical biologists in medical
analysis laboratories, for example, as clinical biologists, and offer a set of references that
may be consulted for more informationstor
more
BACKGROUND: Growing political attention to antimicrobial resistance (AMR) offers a rare opportunity for achieving meaningful action. Many governments have developed national AMR action plans, but most have not yet implemented policy interventions to reduce antimicrobial overuse. A systematic evidenc...e map can support governments in making evidence-informed decisions about implementing programs to reduce AMR, by identifying, describing, and assessing the full range of evaluated government policy options to reduce antimicrobial use in humans.
METHODS AND FINDINGS: Seven databases were searched from inception to January 28, 2019, (MEDLINE, CINAHL, EMBASE, PAIS Index, Cochrane Central Register of Controlled Trials, Web of Science, and PubMed). We identified studies that (1) clearly described a government policy intervention aimed at reducing human antimicrobial use, and (2) applied a quantitative design to measure the impact. We found 69 unique evaluations of government policy interventions carried out across 4 of the 6 WHO regions. These evaluations included randomized controlled trials (n = 4), non-randomized controlled trials (n = 3), controlled before-and-after designs (n = 7), interrupted time series designs (n = 25), uncontrolled before-and-after designs (n = 18), descriptive designs (n = 10), and cohort designs (n = 2). From these we identified 17 unique policy options for governments to reduce the human use of antimicrobials. Many studies evaluated public awareness campaigns (n = 17) and antimicrobial guidelines (n = 13); however, others offered different policy options such as professional regulation, restricted reimbursement, pay for performance, and prescription requirements. Identifying these policies can inform the development of future policies and evaluations in different contexts and health systems. Limitations of our study include the possible omission of unpublished initiatives, and that policies not evaluated with respect to antimicrobial use have not been captured in this review.
CONCLUSIONS: To our knowledge this is the first study to provide policy makers with synthesized evidence on specific government policy interventions addressing AMR. In the future, governments should ensure that AMR policy interventions are evaluated using rigorous study designs and that study results are published.
more
Road safety is an issue that does not receive anywhere near the attention it deserves – and it really is one
of our great opportunities to save lives around the world
This joint publication by UNAIDS and WHO emphasizes the importance of integrating HIV prevention, testing, treatment and care and mental health services for people living with HIV. It provides a compilation of tools, best practices, recommendations and guidelines that facilitate the integration of i...nterventions and services to address the interlinked issues of mental health and HIV. This publication is intended for global, regional and national policy-makers; programme implementers including at subnational levels; organizations working in and providers of HIV and mental health services; civil society; and community-based and community-led organizations and advocates.
more
Em meados de 2021, os programas nacionais de SIDA começaram a fazer a transição do tratamento para crianças que vivem com VIH dolutegravir (DTG) 10 mg sulcado, comprimidos dispersíveis, também conhecido como DTG pediátrico (pDTG). A rápida introdução e implementação do pDTG é uma priori...dade para implementar as diretrizes da Organização Mundial da Saúde (OMS) e garantir que as crianças que vivem com VIH recebam o melhor tratamento disponível da SIDA de primeira e segunda linha o mais rápido possível. É importante notar que uma única substituição pDTG deve ocorrer independentemente da disponibilidade de um teste/carga viral (CV), ou do valor do último resultado de CV, mantendo ou otimizando as crianças usando abacavir/lamivudina (ABC/3TC) como base. Atualmente, mais de 30 países têm planos de adoção e implementação do pDTG.
more
This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical (fifth annual review) development. The analysis covers traditional (direct-acting small molecules) and non-traditional antibacterial agents in development worldwide. It evaluates to what extent... the present pipeline addresses infections caused by WHO Priority Pathogens, Mycobacterium tuberculosis and Clostridioides difficile. The report also provides an assessment of the traditional agents with respect to whether they meet a set of predefined criteria for innovation, namely absence of known cross-resistance, new target, mode of action and/or class. It also includes an overview of the agents that obtained authorization since 1 July 2017.
more
Accessed on 15.08.2022
La farmacovigilancia es una herramienta que permite la detección, evaluación, conocimiento y prevención de efectos adversos y/o inesperados de los medicamentos que se prescriben. También facilita la detección de fallas de respuesta terapéutica por deficiencias de calid...ad.
more